Virax Biolabs (VRAX) Enterprise Value (2021 - 2026)
Virax Biolabs (VRAX) posted quarterly Enterprise Value of -$6.7 million for Q1 2026, down 49.71% year-over-year from -$13.3 million in Q1 2025, and down 49.71% quarter-over-quarter from -$4.5 million in Q1 2025.
Virax Biolabs (VRAX) Enterprise Value (2021 - 2026) Analysis & Trends
Virax Biolabs' Enterprise Value history runs 6 years deep, the most recent figure standing at -$6.7 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 49.71% year-over-year to -$6.7 million; the TTM figure through Mar 2026 stood at -$6.7 million (down 49.71% YoY), while the FY2026 annual figure was -$6.7 million, down 49.71% from the prior year.
- Enterprise Value for Q1 2026 stood at -$6.7 million, down from -$4.5 million in the prior quarter.
- The five-year high for Enterprise Value was -$21756.0 in Q1 2022, with the low at -$9.4 million in Q1 2023.
- The 5-year median for Enterprise Value is -$5.6 million (2025), against an average of -$5.2 million.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value sank 42888.32% in 2023, then soared 61.62% in 2024.
- Virax Biolabs' Enterprise Value stood at -$21756.0 in 2022, then tumbled by 42888.32% to -$9.4 million in 2023, then gained by 22.1% to -$7.3 million in 2024, then surged by 38.75% to -$4.5 million in 2025, then tumbled by 49.71% to -$6.7 million in 2026.
- Business Quant data shows VRAX's Enterprise Value at -$6.7 million in Q1 2026, -$4.5 million in Q1 2025, and -$7.3 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 2.12 Bn |
| 10 | Virax Biolabs | 1.33 Mn | -5.11 Mn | - | -6.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.68 Mn |
| Mar 31, 2025 | -4.46 Mn |
| Sep 30, 2024 | -7.29 Mn |
| Mar 31, 2024 | -3.59 Mn |
| Mar 31, 2023 | -9.35 Mn |
| Mar 31, 2022 | -21,756.00 |
| Mar 31, 2021 | -17,621.00 |